EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Open Access · CC BY 4.0

A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial

Angharad G Davis iD, Sean Wasserman, Cari Stek, Mpumi Maxebengula, C Jason Liang, Stephani Stegmann, Sonya Koekemoer, Amanda Jackson, Yakub Kadernani, Marise Bremer, Remy Daroowala, Saalikha Aziz und 20 weitere

Clinical Infectious Diseases · 2023

DOI: 10.1093/cid/ciac932 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2023. Verfasst von Angharad G Davis und 31 weiteren Autor:innen. Beteiligte Einrichtung: Francis Crick Institute, London, United Kingdom. Hauptthemen laut MEDLINE: Tuberculosis, Meningeal, HIV Infections. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FIC NIH HHS, Wellcome Trust, Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug regimens that include intensified antibiotics alongside effective anti-inflammatory therapies may improve outcomes in tuberculous meningitis (TBM). Safety data on their use in combination and in the context of human immunodeficiency virus (HIV) are needed to inform clinical trial design.

Methods

We conducted a phase 2, open-label, parallel-design, randomized, controlled trial to assess the safety of high-dose rifampicin, linezolid, and high-dose aspirin in HIV-associated TBM. Participants were randomized (1.4:1:1) to 3 treatment arms (1, standard of care [SOC]; 2, SOC + additional rifampicin [up to 35 mg/kg/d] + linezolid 1200 mg/d reducing after 28 days to 600 mg/d; 3, as per arm 2 + aspirin 1000 mg/d) for 56 days, when the primary outcome of adverse events of special interest (AESI) or death was assessed.

Results

A total of 52 participants with HIV-associated TBM were randomized; 59% had mild disease (British Medical Research Council (MRC) grade 1) vs 39% (grade 2) vs 2% (grade 3). AESI or death occurred in 10 of 16 (63%; arm 3) vs 4 of 14 (29%; arm 2) vs 6 of 20 (30%; arm 1; P = .083). The cumulative proportion of AESI or death (Kaplan–Meier) demonstrated worse outcomes in arm 3 vs arm 1 (P = .04); however, only 1 event in arm 3 was attributable to aspirin and was mild. There was no difference in efficacy (modified Rankin scale) between arms.

Conclusions

High-dose rifampicin and adjunctive linezolid can safely be added to the standard of care in HIV-associated TBM. Larger studies are required to determine whether potential toxicity associated with these interventions, particularly high-dose aspirin, is outweighed by mortality or morbidity benefit. Clinical Trials Registration NCT03927313.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tuberculosis, MeningealHIV InfectionsHumansRifampinAntitubercular AgentsAspirinLinezolidHIVTreatment Outcome

Stichwörter der Autor:innen

HIVaspirinlinezolidrifampicintuberculous meningitis

Substanzen

RifampinAntitubercular AgentsAspirinLinezolid

Autor:innen und Institutionen

  • Francis Crick Institute, London, United Kingdom.
  • Faculty of Life Sciences, University College London, London, United Kingdom.
  • Wellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Observatory, Republic of South Africa.
  • Department of Medicine, University of Cape Town, Observatory, Republic of South Africa.
  • Department of Infectious Diseases, Imperial College London, London, United Kingdom.
  • Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA.

ORCID-Profile: Angharad G Davis, Paolo Denti, Gary Maartens

Förderung

  • FIC NIH HHS
  • Wellcome Trust
  • Medical Research Council
  • NIAID NIH HHS
  • a UCL Wellcome Trust PhD Programme for Clinicians fellowship
  • European & Developing Countries Clinical Trials Partnership
  • UKRI;
  • Department of Science and Technology

Zitieren

APA

Davis, A. G., Wasserman, S., Stek, C., Maxebengula, M., Jason Liang, C., Stegmann, S., Koekemoer, S., Jackson, A., Kadernani, Y., Bremer, M., Daroowala, R., Aziz, S., Goliath, R., Lai Sai, L., Sihoyiya, T., Denti, P., Lai, R. P. J., Crede, T., Naude, J., …, & Wilkinson, R. J. (2023). A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciac932

Vancouver

Davis AG, Wasserman S, Stek C, Maxebengula M, Jason Liang C, Stegmann S, et al. A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial. Clinical Infectious Diseases. 2023. doi:10.1093/cid/ciac932

BibTeX
@article{Davis2023,
  author = {Davis, Angharad G and Wasserman, Sean and Stek, Cari and Maxebengula, Mpumi and Jason Liang, C and Stegmann, Stephani and Koekemoer, Sonya and Jackson, Amanda and Kadernani, Yakub and Bremer, Marise and Daroowala, Remy and Aziz, Saalikha and Goliath, Rene and Lai Sai, Louise and Sihoyiya, Thandi and Denti, Paolo and Lai, Rachel P J and Crede, Thomas and Naude, Jonathan and Szymanski, Patryk and Vallie, Yakoob and Banderker, Ismail Abbas and Moosa, Muhammed S and Raubenheimer, Peter and Candy, Sally and Offiah, Curtis and Wahl, Gerda and Vorster, Isak and Maartens, Gary and Black, John and Meintjes, Graeme and Wilkinson, Robert J},
  title = {A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus–Associated Tuberculous Meningitis: The LASER-TBM Trial},
  journal = {Clinical Infectious Diseases},
  year = {2023},
  doi = {10.1093/cid/ciac932}
}
Kostenlos starten →